News Snapshot:
The company’s phase three trial of its Ad5-nCoV vaccine candidate is being tested on some 40,000 participants in Russia, Saudi Arabia, Pakistan and Mexico The last participant in the trial is expected to get the jab at the end of November, before the tests are wrapped up July 31 next year The company’s phase three trial of its Ad5-nCoV vaccine candidate is being tested on some 40,000 participants in Russia, Saudi Arabia, Pakistan and Mexico. CanSino Biologics chose middle and lower-income countries over Western nations to test the effectiveness and safety of its novel coronavirus vaccine candidate as it expected...
